Yutaka Akiyama

Prof. Yutaka Akiyama

Tokyo Institute of Technology, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Chemical Physics Letters
Verified
Journal Article
Closed access
TNTatsuya Nakano
Tatsuya Nakano
TKTsuguchika Kaminuma
Tsuguchika Kaminuma
TSToshiyuki Sato
Toshiyuki Sato
KFKaori Fukuzawa
Kaori Fukuzawa
Yutaka AkiyamaYutaka Akiyama
Yutaka Akiyama
KKKazuo Kitaura
Kazuo Kitaura

1 March 2000 in Chemical Physics Letters
Verified
Journal Article
Closed access
TNTatsuya Nakano
Tatsuya Nakano
TKTsuguchika Kaminuma
Tsuguchika Kaminuma
TSToshiyuki Sato
Toshiyuki Sato
Yutaka AkiyamaYutaka Akiyama
Yutaka Akiyama
MUMasami Uebayasi
Masami Uebayasi
KKKazuo Kitaura
Kazuo Kitaura

1 November 2011 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SFSarel Fleishman
Sarel Fleishman
TWTimothy A. Whitehead
Timothy A. Whitehead
ESEva-Maria Strauch
Eva-Maria Strauch
JCJacob E. Corn
Jacob E. Corn
SQSanbo Qin
Sanbo Qin
DBDavid Baker
David Baker

17 March 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
JLJianan Li
Jianan Li
Keisuke YanagisawaKeisuke Yanagisawa
Keisuke Yanagisawa
MSMasatake Sugita
Masatake Sugita
TFTakuya Fujie
Takuya Fujie
Masahito OhueMasahito Ohue
Masahito Ohue
Yutaka AkiyamaYutaka Akiyama
Yutaka Akiyama
Recently, cyclic peptides have been considered breakthrough drugs because they can interact with “undruggable” targets such as intracellular protein–protein interactions. Membrane permeability is an essential indicator of oral bioavailability and intracellular targeting, and the development of membrane-permeable peptides is a bottleneck in cyclic peptide drug discovery. Although many experimental data on membrane permeability of cyclic peptides have been reported, a comprehensive database is not yet available. A comprehensive membrane permeability database is essential for developing computational methods for cyclic peptide drug design. In this study, we constructed CycPeptMPDB, the first web-accessible database of cyclic peptide membrane permeability. We collected information on a total of 7334 cyclic peptides, including the structure and experimentally measured membrane permeability, from 45 published papers and 2 patents from pharmaceutical companies. To unambiguously represent cyclic peptides larger than small molecules, we used the hierarchical editing language for macromolecules notation to generate a uniform sequence representation of peptides. In addition to data storage, CycPeptMPDB provides several supporting functions such as online data visualization, data analysis, and downloading. CycPeptMPDB is expected to be a valuable platform to support membrane permeability research on cyclic peptides. CycPeptMPDB can be freely accessed at http://cycpeptmpdb.com.

6 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSShuji Suzuki
Shuji Suzuki
MKMasanori Kakuta
Masanori Kakuta
TITakashi Ishida
Takashi Ishida
Yutaka AkiyamaYutaka Akiyama
Yutaka Akiyama
DNA sequences are translated into protein coding sequences and then further assigned to protein families in metagenomic analyses, because of the need for sensitivity. However, huge amounts of sequence data create the problem that even general homology search analyses using BLASTX become difficult in terms of computational cost. We designed a new homology search algorithm that finds seed sequences based on the suffix arrays of a query and a database, and have implemented it as GHOSTX. GHOSTX achieved approximately 131–165 times acceleration over a BLASTX search at similar levels of sensitivity. GHOSTX is distributed under the BSD 2-clause license and is available for download at http://www.bi.cs.titech.ac.jp/ghostx/. Currently, sequencing technology continues to improve, and sequencers are increasingly producing larger and larger quantities of data. This explosion of sequence data makes computational analysis with contemporary tools more difficult. We offer this tool as a potential solution to this problem.

6 August 2014 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Masahito OhueMasahito Ohue
Masahito Ohue
TSTakehiro Shimoda
Takehiro Shimoda
SSShuji Suzuki
Shuji Suzuki
YMYuri Matsuzaki
Yuri Matsuzaki
TITakashi Ishida
Takashi Ishida
Yutaka AkiyamaYutaka Akiyama
Yutaka Akiyama
Summary: The application of protein–protein docking in large-scale interactome analysis is a major challenge in structural bioinformatics and requires huge computing resources. In this work, we present MEGADOCK 4.0, an FFT-based docking software that makes extensive use of recent heterogeneous supercomputers and shows powerful, scalable performance of >97% strong scaling. Availability and Implementation: MEGADOCK 4.0 is written in C++ with OpenMPI and NVIDIA CUDA 5.0 (or later) and is freely available to all academic and non-profit users at: http://www.bi.cs.titech.ac.jp/megadock . Contact:akiyama@cs.titech.ac.jp Supplementary information: Supplementary data are available at Bioinformatics online